Regarding background HF therapy, there were no significant differences between the groups with respect to treatment with an angiotensin-converting enzyme inhibitor (ACEi)/ARB, beta-blocker, or mineralocorticoid receptor antagonist. This evidence concerns the gene NR3C2 and hydrops fetalis.